Evaluation of Pulmonary Fibrosis After Severe Interstitial Pneumonia Due to COVID-19 (SARS-CoV-2)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- The magnitude of pulmonary involvement
研究概览
简要总结
Patients discharged after hospitalization for COVID-19 pneumonia were retrospectively selected by radiologically established criteria that at admission presented at chest computed tomography (CT) (i) normal lung parenchyma <50% of total lung volume; and/or (ii) area of lung consolidation > 10%. All At discharge and after 9 months, all subjects underwent cardiological evaluation, echocardiogram, pulmonary function tests (PFT) both atby 3 and by 12 months after discharge. Chest CT was performed by 12 months after discharge and chest CT. Specifically, the magnitude of pulmonary involvement between baseline and follow-up was considered the primary endpoint of this study. Secondary endpoints of the study were results of respiratory function testing, echocardiographic parametersparameters, and persistence of symptoms.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hospitalization for severe COVID-19 pneumonia
- •Computed tomography during index hospitalization that showed: (i) normale lung parenchyma < 50% of total lung volume and/or (ii) parenchymal consolidation > 10%
- •Cardiological and pneumological visit, echocardiography and pulmonary function test at 3 and 12 months from hospital discharge
- •Computed tomography by 12 months from hospital discharge
排除标准
- •Age < 18
- •Absence of previously cited test.
结局指标
主要结局
The magnitude of pulmonary involvement
时间窗: 12 months
次要结局
- results of respiratory function testing(12 months)
- echocardiographic parameters(12 months)
- persistence of symptoms(12 months)
研究者
Gabriele Fragasso
Principal Investigator
IRCCS San Raffaele